Healthcare services provider BrightSpring Health Services (NASDAQ: BTSG) announced better-than-expected revenue in Q1 CY2026, with sales up 25.6% year on year to $3.61 billion. The company’s full-year revenue guidance of $14.98 billion at the midpoint came in 0.9% above analysts’ estimates. Its GAAP profit of $0.67 per share was significantly above analysts’ consensus estimates.

Is now the time to buy BrightSpring Health Services? Find out by accessing our full research report, it’s free.

"We are pleased with the Company’s first quarter results, which reflect the team’s commitment to patients as well as the operating and growth priorities discussed at the Investor Day in March,” said Jon Rousseau, Chairman, President, and Chief Executive Officer of BrightSpring.

Company Overview

Founded in 1974, BrightSpring Health Services (NASDAQ: BTSG) offers home health care, hospice, neuro-rehabilitation, and pharmacy services.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Over the last five years, BrightSpring Health Services grew its sales at an impressive 19.5% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. BrightSpring Health Services’s annualized revenue growth of 22.6% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated.

BrightSpring Health Services also breaks out the revenue for its most important segment, Pharmacy. Over the last two years, BrightSpring Health Services’s Pharmacy revenue averaged 29.6% year-on-year growth. This segment has outperformed its total sales during the same period, lifting the company’s performance.

This quarter, BrightSpring Health Services reported robust year-on-year revenue growth of 25.6%, and its $3.61 billion of revenue topped Wall Street estimates by 6.3%.

Looking ahead, sell-side analysts expect revenue to grow 12.2% over the next 12 months, a deceleration versus the last two years. We still think its growth trajectory is attractive given its scale and indicates the market is baking in success for its products and services.

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.

Adjusted Operating Margin

BrightSpring Health Services’s adjusted operating margin has generally stayed the same over the last 12 months, averaging 3.8% over the last five years. This profitability was paltry for a healthcare business and caused by its suboptimal cost structure.

Looking at the trend in its profitability, BrightSpring Health Services’s adjusted operating margin might fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability.

In Q1, BrightSpring Health Services generated an adjusted operating margin profit margin of 3.5%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Sadly for BrightSpring Health Services, its EPS declined by 12.7% annually over the last five years while its revenue grew by 19.5%. However, its adjusted operating margin didn’t change during this time, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings.

Diving into the nuances of BrightSpring Health Services’s earnings can give us a better understanding of its performance. BrightSpring Health Services recently raised equity capital, and in the process, grew its share count by 84.5% over the last five years. This has resulted in muted earnings per share growth but doesn’t tell us as much about its future. We prefer to look at operating and free cash flow margins in these situations.

In Q1, BrightSpring Health Services reported EPS of $0.67, up from $0.14 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects BrightSpring Health Services’s full-year EPS of $1.41 to grow 3.2%.

Key Takeaways from BrightSpring Health Services’s Q1 Results

It was good to see BrightSpring Health Services beat analysts’ revenue and EPS expectations this quarter. We were also excited its full-year guidance for revenue was raised and full-year guidance for EBITDA outperformed Wall Street’s estimates. Zooming out, we think this was a very solid print. The stock remained flat at $48.30 immediately following the results.

BrightSpring Health Services had an encouraging quarter, but one earnings result doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. When making that decision, it’s important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here (it’s free).